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Abstract 
Multiple myeloma (MM) is a hematological plasma cell malignancy in the bone marrow. 
Lately, increased knowledge of MM pathogenesis and advances in therapy have improved 
the survival of MM patients. However, due to the unique and complex genome of each 
patient, some patients are resistant to standard therapies while others achieve durable 
response but eventually experience relapse. Therefore, new strategies especially for 
relapsed and refractory and high-risk multiple myeloma (RRMM, HRMM) patients, who 
have poor response to current therapies, are required. Melflufen, a novel prodrug of the 
alkylating agent melphalan, has shown significantly decreased resistance effects and 
more selective cytotoxicity compared to melphalan in vitro and in vivo, but the molecular 
markers identifying the sensitive subgroups of MM patients have not yet been discovered. 
The aim of this study was to identify a melflufen-sensitive subgroup of MM patients by 
utilizing a high throughput flow cytometry-based drug sensitivity testing platform. For 
the assessment, mononuclear cells from bone marrow of MM patients were derived and 
melflufen sensitivity of different cell populations tested. As a result, malignant plasma 
cells were significantly more sensitive to melflufen than to melphalan. Importantly, all 
MM patient samples including RRMM and HRMM patients were sensitive to melflufen 
although to varying degrees suggesting these patients may benefit from melflufen 
treatment. Further integration of the results with additional molecular information may 
lead to discovery of new biomarkers and thus the prediction of melflufen responses can 
result in more effective disease management and save patients from ineffective therapies. 
Keywords: multiple myeloma, melflufen, personalized medicine
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1 Introduction 
1.1 Multiple myeloma 
Multiple myeloma (MM) is a heterogenous and hematological plasma cell malignancy. 
Plasma cells (PCs) are type of blood cells derived from the lymphoid B-cell lineage 
during hematopoiesis which is defined as the formation of blood cell components 
(Jagannathan-Bogdan and Zon, 2013). These components originate from self-renewing 
hematopoietic stem cells, which are differentiated to either lymphoid progenitor cells, 
lymphoblasts, lymphocytes and plasma cells (Fig. 1), or to myeloid progenitor cells, 
granulocytes, erythrocytes, megakaryocytes and macrophages. During development, B 
cells mature in the lymph organs, where they undergo somatic hypermutation. They 
eventually return to the bone marrow (BM) as terminally differentiated PCs and produce 
and secrete antibodies essential for normal function of the immune system. However, in 
MM, malignant monoclonal PCs replace normal PCs in the BM, resulting in 
overabundance of clonal antibodies. Also, the number of normal blood cells and 
functional antibodies are decreased. 
 
Figure 1. The plasma cells are originated from lymphoid B-cell linage. Blood cells are derived from hematopoietic 
stem cells either by lymphoid or myeloid lineage. During hematopoiesis of the lymphoid linage, hematopoietic stem 
cells proliferate to lymphoid progenitor cells, lymphoblasts, lymphocytes and finally to plasma cells. 
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1.1.1 Incidence, Disease Progression and Risk Factors 
MM accounts for 1% of all cancers and 10–15% of hematologic malignancies, and is the 
second most common hematologic cancer worldwide (Rajkumar, 2018). In the United 
States, over 30 000 new cases and over 12 000 deaths of MM are reported each year 
(Siegel et al., 2015), while the estimated 5-year prevalence is about 230 000 patients 
worldwide (Kazandjian, 2016). Furthermore, median age of patients diagnosed with MM 
is approximately 65 years, and the ratio between male and female patients is 1.4:1 
indicating that the disease is slightly more common in males than females (Kyle et al., 
2003). 
MM begins often as monoclonal gammopathy of undetermined significance (MGUS), 
which progresses to smoldering multiple myeloma (SMM) and finally develops to MM. 
MGUS is usually asymptomatic and has been present in the patients for more than 10 
years prior to the diagnosis (Therneau et al., 2012). It progresses to MM at a rate of 1% 
per year (Kyle et al., 2002). In contrast, SMM patients usually do not have any symptoms, 
but they have paraprotein in the blood and clonal PCs in the BM (10–60%) without any 
organ or tissue damage. During the first five years after diagnosis, SMM progresses to 
MM at a rate of 10% per year, over the next five years 3% per year and thereafter 1.5% 
per year (Rajkumar, 2018). Lastly, MM can develop into plasma cell leukemia in which 
clonal PCs disseminate from the BM, are independent of the BM microenvironment and 
can survive in the blood (Gundesen et al., 2019). 
Although risk factors of MM are poorly understood, there are some factors that are 
observed to increase the risk of developing MM in addition to age and male sex. These 
are MGUS and SMM, a family history of MGUS, SMM, MM or other B-cell malignancy 
(Brigle and Rogers, 2017), and environmental or occupational exposure to ionizing 
radiation, asbestos, industrial chemicals, benzene and pesticides (Eriksson and Karlsson, 
1992). Also, long-lasting exposure to antigens used as a treatment for example in chronic 
infections and rheumatoid arthritis can predispose to MM. 
1.1.2 Clinical Features and Diagnosis 
The imbalance of blood cells causes the common symptoms of MM such as a weakened 
immune system and continuous infections, anemia and tiredness, as well as abnormal 
bruising and bleeding (Kyle and Rajkumar, 2008). Also, skeletal fractures and bone pain 
are quite common accounting for 58% of cases at diagnosis (Brigle and Rogers, 2017), 
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which result in calcium release into the bloodstream and therefore hypercalcemia 
(Fairfield et al., 2016). Additionally, fatigue, weight loss and renal dysfunction are often 
observed. However, when MM is diagnosed, nonspecific symptoms for an extended 
period of time are usually presented, which challenges diagnosis. 
The criteria for MM diagnosis are recommended by the International Myeloma Working 
Group (IMWG) and World Health Organization (WHO) (Rajkumar et al., 2014). The 
diagnosis requires either plasmacytoma proved by biopsy or examination of clonal PCs 
on BM, in addition to one of more myeloma defining events (MDE). MDE consists of 
CRAB (hypercalcemia, renal failure, anemia, lytic bone lesions) and three specific 
biomarkers: 1) clonal BM PCs ≥60%; 2) serum free light chain ratio ≥100; and 3) at least 
5mm diameter focal lesion(s) on magnetic resonance imaging (MRI). 
1.1.3 Molecular Classification, Genetic Complexity and Risk Stratification 
Antibodies, also known as immunoglobulins, consist of two immunoglobulin heavy (IgH) 
and two light chains (IgL). In MM, the most common abnormal chains are IgG and IgA 
heavy chains. There is also possibility that only light chains are produced, however in 
these cases, the prognosis of patients is poorer and the frequency of additional disorders 
such as renal failure and amyloidosis is higher compared to patients with IgG and IgA 
subtypes (Zhang et al. 2014). In addition, the differences of IgL subtypes (kappa and 
lambda) and their influence on MM outcome and progression have not yet been studied 
in more detail (Zhang et al. 2014). 
The genome of the myeloma cell has multiple structural alterations and mutations in 
several oncogenes and tumor suppressor genes and thus displays genomic instability. 
Primary cytogenetic abnormalities can be divided into two subgroups based on 
fluorescent in situ hybridization (FISH) of BM and the karyotype of the patients 
(Bergsagel and Chesi, 2013). 40–50% of patients have hyperdiploid karyotype which is 
characterized by odd-numbered chromosomes including trisomies in chromosomes 3, 5, 
7, 9, 11, 15, 19 and 21. In contrast, hypodiploid karyotype is characterized by frequent 
translocations in the IgH and the loss of chromosomes 13, 14, 16, and 22. Importantly, 
hyperdiploid karyotype has a better prognosis than hypodiploid karyotype. 
Secondary cytogenetic abnormalities occur during the MM progression and often cause 
the invasion of myeloma cells from the BM. These changes include RAS mutations, MYC 
translocations and aberrations such as del(17p) which is the locus of TP53 gene, gain(1q) 
4 
 
locus of MCL1, CKS1B, ANP32E and BCL9 genes, and del(13q) the locus of RB1, DIS3, 
mir15a and mir16.1 genes, which all are related to cancer development and progression 
(Castaneda and Baz, 2019). Since chromosomal translocations are already observed in 
MGUS and SMM stages, there is evidence that aberrant DNA repair is involved in disease 
progression (Castaneda and Baz, 2019). Additionally, at the later stages of MM, signaling 
pathways are disturbed, the BM microenvironment becomes more favorable to malignant 
PCs and begins to nurture and support the proliferation of these cells, and epigenetic 
changes, such as DNA methylation and micro-RNA changes, are observed (Rajkumar, 
2018). The primary and secondary genomic events in MM are presented in Table 1. 
Table 1. The primary and secondary genomic events in multiple myeloma (MM) with the frequency and 
prognostic value. Adapted from “Multiple Myeloma Genomics - A Concise Review” by Castaneda and Baz, 2019. 
 
The International Staging System (ISS) divides MM into three stages based on serum β2-
macroglobulin (β2-M) and albumin measurements. Since the staging system does not take 
into account karyotype information, which is the most important prognostic factor in MM, 
the Revised International Staging System (RISS) was created by the IMWG to combine 
elements of both tumor burden and disease biology (Rajkumar et al., 2014). In stage 1 
(low-risk), serum albumin is more than 3.5 gm/dl, β2-M is less than 3.5 mg/l, there is no 
high-risk cytogenetics, and serum lactate dehydrogenase level is normal. In contrast, in 
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the stage 3 (high-risk), serum β2-M is more than 5.5 mg/l and it has high-risk cytogenetics 
– t(4;14), t(14;16), or del(17p) – or elevated serum lactate dehydrogenase level. Stage 2 
(standard-risk) does not fit in neither stage 1 nor 3. Although any cytogenetic abnormality 
is considered as high-risk MM (HRMM), some of the abnormalities are considered as 
poor-risk markers. For example, the 8-year survival rate of patients with del(17p) has 
been identified as 52%, t(4;14) translocation 33%, and gain(1q) abnormality 36% 
indicating the worst prognosis among the cytogenetic aberrations (Majumder et al., 
2017).  
1.1.4 Current Treatment 
The pipeline for treating MM is one of the most diverse in oncology. Treatment options 
for MM include alkylators (melphalan, doxorubicin), steroids (dexamethasone, 
prednisone), immunomodulators (thalidomide, lenalidomide, pomalidomide), 
proteasome inhibitors (bortezomib, carfilzomib), histone deacetylase (HDAC) inhibitors 
(panobinostat), monoclonal antibodies (daratumumab, elotuzumab) and nuclear export 
inhibitors (selinexor), which are used individually or in combination. The choice of 
treatment depends on the presence or absence of cytogenetic features and the progression 
stage (initial treatment, maintenance treatment, relapse treatment). Moreover, one of the 
main problems of MM treatment is adverse effects such as secondary leukemia caused by 
chemotherapy of used drugs. Hence, only MM with symptoms is treated. 
If a patient with low or standard-risk cytogenetic aberrations is eligible, initial treatment 
is usually started with stem cell transplant in combination with multi-drug therapy such 
as bortezomib-containing regimens or lenalidomide with dexamethasone (Mateos and 
San Miguel, 2017). For most patients, lenalidomide is the standard drug for maintenance 
therapy after the transplant. For high-risk patients, carfilzomib‐lenalidomide‐
dexamethasone combination is recommended as initial therapy and proteasome inhibitor-
based regimens as maintenance therapy. 
Unfortunately, stem cell transplantation is an intensive treatment method meaning that it 
is valid for only a small number of patients such as young patients. Therefore, older 
patients are often treated with less intensive methods. Initial therapy is preferred to be 
bortezomib-lenalidomide-dexamethasone, followed by lenalidomide maintenance in low 
and standard-risk patients, and bortezomib maintenance in high-risk patients. In frail 
elderly patients, initial therapy is often started with lenalidomide-dexamethasone and 
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followed until progression. If patient is not eligible for lenalidomide treatment, 
melphalan-based regimens are also recommended (Rajkumar, 2018). 
Although some patients respond well to treatment and reach stable disease stage, 
eventually almost all patients will develop resistance to therapy and experience relapse. 
The duration of remission decreases with each regimen (Kumar et al., 2004). Many 
factors, such as the timing of the relapse, response to prior therapy, aggressiveness of the 
relapse, and performance status (TRAP) affects the choice of therapy. A triplet regimen, 
of which at least two drugs are new and patient is not refractory to, especially proteasome 
inhibitors and monoclonal antibodies, are highly used (Rajkumar, 2018). When treating 
relapsed and refractory MM (RRMM) patients, the focus is in palliative treatment and 
providing as good quality of life (QoL) as possible (Sonneveld and Broijl, 2016). 
1.2 Melphalan and melflufen 
Melphalan is a classical alkylating chemotherapeutic drug developed in 1953 for various 
malignancies such as ovarian and breast cancers, lymphomas, leukemia and MM 
(Bayraktar et al., 2013). It has increased the lifespan of patients for a several years 
(Trippoli et al., 1998) and it has been used in clinics mainly as combination chemotherapy 
(Wickström et al., 2008). Therefore, melphalan has proved its important role in MM 
therapy. However, especially with higher doses, it has cytotoxic and drug-resistant effects 
(Chauhan et al., 2013), and thus some novel biological drugs have replaced it. Hence, the 
melphalan prodrug melphalan flufenamide ethyl ester (melflufen, previously denoted as 
J1) (Fig. 2), was developed by Oncopeptides AB to achieve more targeted efficacy and 
hence more specific responses and less adverse effects. 
 
Figure 2. The chemical structure of melphalan and its prodrug melflufen. The difference between structures of 
(A) melphalan and (B) melflufen is circled. Structures are from PubChem, accessed Aug 16, 2019, from 
https://pubchem.ncbi.nlm.nih.gov/. 
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Melflufen, a lipophilic peptide-conjugated alkylator, has a novel mechanism of action in 
MM (Fig. 3). Specific aminopeptidases, which are important for normal cellular function, 
are highly expressed in several malignant cells and are associated with tumor cell 
invasion, differentiation and proliferation (Wickström et al., 2011). Melflufen is 
potentiated by these aminopeptidases and due to its high lipophilicity (logP 4.04) it is able 
to rapidly penetrate membranes of malignant PCs (Wickström et al., 2017). Immediate 
enzymatic cleavage of the peptide bond of melflufen by specific peptidases causes high 
intracellular concentrations of melphalan inducing extensive DNA damage and 
eventually apoptosis (Wickström et al., 2017). 
 
Figure 3. The mechanism of action of melflufen. 1. Specific peptidases are expressed in MM cells. 2. Due to its high 
lipophilicity, melflufen is rapidly taken up by malignant plasma cells. 3. Inside the cells, melflufen is immediately 
cleaved by the specific peptidases. 4. The melphalan payloads are entrapped. 5. Melflufen induces DNA damage 
leading to apoptosis of malignant plasma cells. Adapted from “Mechanism of Action”, accessed Aug 29, 2019, from 
https://www.oncopeptides.se/en/mechanism-of-action/ 
The potential use of melflufen has been studied for several malignancies including 
hematological cancers, such as lymphoma (Delforoush et al., 2016) and leukemia (Strese 
et al., 2017), as well as solid malignancies (Berglund et al., 2015), such as urothelial 
carcinoma (Viktorsson et al., 2016) and ovarian cancer (Carlier et al., 2016). It has been 
shown that despite identical alkylating capacity, melflufen has significantly higher 
activity, more selective cytotoxicity and decreased resistance effects in vitro compared to 
melphalan (Ray et al., 2016; Wickström et al., 2010; Wickström et al., 2017). 
Furthermore, melflufen has 67-fold lower IC50 values than melphalan in hematological 
malignancies ex vivo (Wickström et al., 2008). 
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In addition, melflufen has been tested in vivo in rodents with conventional xenograft 
models and hollow fiber models (Chauhan et al., 2013; Chesi et al., 2012; Gullbo et al., 
2004). For example, Chauhan et al. investigated a significant delay in tumor growth and 
prolongation of survival in SCID mice xenografted with myeloma cells treated with 
melflufen (Chauhan et al., 2013). Despite an expected short half-life in the blood 
circulation (1 h), melflufen does not exhibit decreased activity when compared to 
melphalan (Gullbo et al., 2003). Recently, melflufen has also shown promising results 
for late-stage MM and hence it is currently in phase III clinical trials for RRMM (“NIH 
Clinical Trial OCEAN”, study identifier NCT03151811). 
1.3 Precision and personalized medicine 
A single drug can be either therapeutically effective, toxic or non-responsive among a 
large group of patients. Therefore, a precision and personalized medicine approach – to 
get the right drugs to the right patients at the right time – has been utilized especially in 
the field of oncology. For example, trastuzumab for HER2 positive breast cancer, 
panitumumab for KRAS positive colorectal cancer and niraparib for BRCA1 and 2 
positive ovarian cancer have been developed and approved by United States Food and 
Drug Administration (FDA) (Saadeh, Bright and Rustem, 2019). Moreover, 
individualized medicine approaches are also seen among novel RRMM therapies 
including panobinostat targeting HDACs (Maiso et al., 2006) and venetoclax targeting 
BCL-2 (Kumar et al., 2017). 
Precision and personalized medicine is based on genomic characterisation of normal and 
cancer genomes in individual patients and guidance of targeted treatments. For robust 
utilization, patients should be stratified based on these cytogenetic markers for better 
prediction of drug responses and disease progression. Consequently, MM patients should 
be stratified based on individual cytogenetic groups rather than heterogeneous risk 
categories (Rajkumar, 2018), and be identified prior the initial therapy for predicting 
treatment responses in each patient and for achieving the maximal response and benefit. 
It can also minimize adverse events and costs of treatments. However, one of the main 
challenges of personalized medicine is the dependence of available biomarkers which are 
needed for the prediction of safety and efficacy of novel drugs. 
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1.4 High throughput flow cytometry-based drug sensitivity testing 
Flow cytometry is a technique used for identifying different cell populations from cell 
suspension. Microscopic particles such as cells and chromosomes flow individually 
through laser light beam where their scattering and possible fluorescence emitting can be 
detected. The scattering can be measured in two different angles: 1) forward scatter (FSC) 
which is comparable to cell size, and 2) side scatter (SSC) which is relative to the 
granularity or internal complexity of the cells. Additionally, fluorescence dyes, usually 
fluorophores conjugated into antibodies, can be utilized at different wavelengths. Cells 
are usually labelled with several different fluorophores for detecting different cell 
populations. 
Immunophenotyping is the clinical application of flow cytometry used for defining 
differentiation linage and stage of cells based on the antigens expressed on the surface of 
the cells. In MM, immunophenotyping can be used for 1) differential diagnosis from other 
hematological diseases and lymphomas, 2) predicting the development of MGUS and 
SMM into MM, 3) defining different subtypes, and 4) defining the remission stage when 
monitoring the treatment responses (Jelinek et al., 2017). By using immunophenotyping 
and cell surface molecules (cluster of differentiation, CD), malignant PCs can be 
separated from the other cell populations by using CD138 and CD38 markers. The most 
widely used CD markers for separating healthy and malignant PCs are CD19, CD20, 
CD27, CD28, CD33, CD45, CD54, CD56, CD81 CD117, CD200 and CD307 (Flores-
Montero et al., 2016; Jelinek et al., 2017). For example, 90% of malignant PCs are CD19-
, 99% CD45-/CD45low and 70% CD56+ (Kuehl and Bergsagel, 2012; Pérez-Persona et 
al., 2007). By contrast, healthy PCs usually express CD19 and CD45 markers while 
lacking CD56. However, there is an ongoing debate regarding the expressed markers of 
malignant PCs, and therefore what are the proper CD markers for identifying malignant 
PCs from healthy ones. 
To utilize this cell population separation, a high throughput, multiparametric, flow 
cytometry-based drug sensitivity and resistance testing (DSRT) platform has been set up 
and performed previously (Javarappa et al., 2018; Kuusanmäki et al., 2019; Majumder et 
al., 2019). It is based on detecting the responses of drugs in specific cell populations 
including malignant cells and other healthy cell populations. The platform can be used 
for validating the most effective therapy options for individual patients by identifying 
molecular signaling pathways and genetic markers of drug responses (Saarela et al., 
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2014). Importantly, inefficient therapies can be avoided, new combinational therapy 
possibilities provided, and drug sensitivities linked to the predictive biomarkers. 
1.5 The aim of the study 
Despite the increased knowledge of the MM genome and improved survival of MM 
patients due to advances in therapy, there are still unmet medical needs with the treatment 
of MM as mentioned above. First, due to the unique and complex genome of each patient, 
some patients are resistant to standard therapies while others initially achieve long, 
durable response. Second, almost every patient will experience relapsed stage and 
eventually become resistant to standard therapies. Third, adverse effects, such as 
development of secondary leukemia remain a major problem. Therefore, new strategies 
and personalized medicine approaches for MM treatment, especially for HRMM and 
RRMM patients, who have poor responses to few available treatment options and who 
have the worst prognosis among the MM patients, are required. Thus, the first aim of this 
study was to show that melflufen is more effective drug than melphalan ex vivo using a 
multiparametric, flow cytometry-based DSRT platform. In addition, other drugs were 
also tested but the results were not included in this thesis. The second aim was to identify 
melflufen-sensitive subgroup(s) of MM patients. Furthermore, the overall goal is to 
unveil MM specific mutations or gene expression patterns by integrating our results with 
molecular profiling for new biomarker discovery in the future. The workflow of the study 
is presented in Figure 4. 
 
Figure 4. The workflow of the study. Briefly, the sensitivity of mononuclear cells isolated from bone marrow of 
individual MM patients were tested to melflufen and melphalan in seven concentrations. On day three, fluorescently 
labelled antibodies specific for different cell surface and viability markers were added to the cells for detecting plasma 
cells and other healthy cell populations, and read with a high-throughput flow cytometer. After data analysis, the 
objective was to observe whether melflufen is more effective than melphalan and stratify patients into melflufen-
sensitive subgroup(s) based on clinical characteristics and cytogenetic factors. Furthermore, the goal is to integrate the 
results with molecular profiling for new biomarker discovery and individualized drug treatment in the future. 
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2 Results 
2.1 Selected samples and clinical characteristics of patients 
On day three, 16 chosen samples had reasonable cell viability (mean 50.70%, SD 0.14%) 
and number of CD138+/CD38+ (malignant PCs) cells in control dimethyl sulfoxide 
(DMSO) wells (mean 1236.3 cells, SD 1713.0 cells) (Appendix 1), which is 10.7% (SD 
13.8%) from all live cells. The 16 samples came from 15 MM patients from which two 
samples were from the same patient at diagnosis and relapse stages. 
Clinical characteristics of the patients are presented in Table 2 (for detailed characteristics 
of each patient, see Appendix 2). The average age of the patients at diagnosis was 64 
years (SD 11.8 years), 7 (47%) were younger than 65 years and 8 (53%) older than 65 
years. 7 (44%) were from newly diagnosed and 9 (56%) RRMM patients, and 6 (40%) 
were female and 9 (60%) male. 4 (25%) patients had not been previously treated, while 7 
(44%) and 5 (31%) had received 1-2 or more than 3 lines of treatment, respectively. Based 
on ISS, 2 (13%) patients were scored with 1, 5 (33%) with 2 and 4 (27%) with 3. 3 (20%) 
patients had IgA and 6 (40%) IgG heavy chain, while 9 (60%) had kappa and 3 (20%) 
lambda light chain. 3 (20%) patients had only light chain without heavy chains. 8 (53%) 
of the patients had high-risk cytogenetic markers del(17p) and/or t(4;14). The majority of 
patients, 11 (73%) and 13 (87%), also had common MM cytogenetic aberrations del(13q) 
and gain(1q), respectively. ISS, IgH and IgL data was not available (NA) for all the 
patients (for 4 (27%), 6 (40%) and 3 (20%) patients, respectively). 
Table 2. Clinical characteristics of patients and drug sensitivity scores (DSSs) after melflufen treatment. Patients 
were stratified based on age at diagnosis, disease status, gender, treatment line, international staging system (ISS), 
immunoglobulin heavy and light chains, and presence of del(13q), gain(1q) and high-risk (del(17p) and/or t(4;14)) 
aberrations. RRMM=relapsed and refractory multiple myeloma, NA=not available, IgL=immunoglobulin light chain. 
Characteristic Distribution of 
patients 
n (%) Mean DSS (SD or 
Q1, Q3) 
p 
Age at diagnosis 
(years) 
<65 
≥65 
7 (46.7) 
8 (53.3) 
38.19 (6.07) 
36.32 (8.73) 
0.6387 
Disease status Diagnosis 
RRMM 
7 (43.75) 
9 (56.25) 
34.34 (8.08) 
39.31 (6.67) 
0.1987 
Gender Female 
Male 
6 (40) 
9 (60) 
37.23 (8.03) 
37.08 (7.62) 
0.9700 
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Treatment line 0 
1-2 
≥3 
4 (25) 
7 (43.75) 
5 (31.25) 
34.25 (31.10, 37.30) 
35.60 (30.60, 45.30) 
44.00 (42.70, 44.00) 
0.4113 
ISS 1 
2 
3 
NA 
2 (13.3) 
5 (33.3) 
4 (26.7) 
4 (26.7) 
38.25 (33.80, 42.70) 
38.75 (26.85, 44.65) 
31.20 (27.90, 38.85) 
 
0.8606 
Immunoglobulin 
heavy chain 
IgA 
IgG 
NA 
3 (20) 
6 (40) 
6 (40) 
35.90 (10.87) 
37.62 (4.84) 
0.7380 
Immunoglobulin 
light chain 
Kappa 
Lambda 
NA 
9 (60) 
3 (20) 
3 (20) 
34.64 (7.62) 
41.53 (3.21) 
0.1644 
Presence of 
immunoglobulins 
IgA 
IgG 
IgL only 
NA 
3 (20) 
6 (40) 
3 (20) 
3 (20) 
35.90 (10.87) 
37.62 (4.84) 
33.90 (SD 8.75 
0. 8016 
del(13q) Yes 
No 
11 (73.3) 
4 (26.7) 
36.12 (7.78) 
40.20 (6.54) 
0.3638 
gain(1q) Yes 
No 
13 (86.7) 
2 (13.3) 
38.84 (6.88) 
29.77 (6.17) 
0.3638 
High-risk 
cytogenetic 
markers 
Both 
del(17p) alone 
t(4;14) alone 
None 
1 (6.7)  
3 (20) 
4 (26.6) 
7 (46.7) 
26.85 (23.30, 30.40) 
42.70 (33.80, 45.30) 
37.30 (33.65, 42.65) 
39.60 (31.80, 44.00) 
0.2319 
 
2.2 Drug responses in malignant plasma cells 
Dose responses of melflufen and melphalan in malignant PCs among all 16 samples (Fig. 
5A) and in each sample individually (Fig. 5B) showed that melflufen was more potent 
drug than melphalan. Mean drug sensitivity score (DSS, for definition see section 4.4.3) 
of melflufen was 37.14 (SD 7.51) and of melphalan 15.47 (SD 4.76) in malignant PCs 
(Appendix 3), and DSSs of melflufen were significantly higher compared to DSSs of 
 8 
(53.3) 
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melphalan (p<0.0001) (Fig. 5C). Also, Pearson correlation showed that responses of 
melflufen and melphalan were not significantly associated (r=0.22, p=0.41) (Fig. 5D). 
Since all samples had high DSS and thus seemed to be sensitive to melflufen, the 
responses in malignant PCs were stratified into more (<50nM) and less (>50nM) sensitive 
subgroups (Appendix 4A) rather than sensitive and resistant groups. However, when 
DSSs of melflufen in these subgroups were compared, there was no statistically 
significant difference (p=0.1599) (Appendix 4B). 
 
Figure 5. The responses of melflufen and melphalan in malignant plasma cells. The dose-response curves of 
melflufen and melphalan (A) from all 16 MM patients, and (B) from individual patients showed that melflufen was 
more potent drug than melphalan. (C) When drug sensitivity scores (DSSs) of drugs in malignant plasma cells were 
compared, DSSs of melflufen were significantly higher than DSSs of melphalan (p<0.0001). (D) Pearson correlation 
showed no significant association between DSS of melflufen and melphalan (r=0.22, p=0.41). Blue=melflufen, 
grey=melphalan. DSS values are presented as means in Fig. 5C. 
2.3 Identification of melflufen-subgroups 
Although all samples seemed to be sensitive to melflufen, to assess whether clinical 
characteristics of MM patients affected the responses of melflufen, patients were stratified 
into different subgroups (Table 2). First, to observe whether disease status and the number 
of received treatment lines had influence on melflufen responses, patients were stratified 
into diagnosis and relapsed groups, and 0, 1-2 and ≥3 treatment line groups. Mean DSS 
of melflufen was 34.34 (SD 8.08) for diagnosed patients and 39.31 (SD 6.67) for relapsed 
patients (Table 2). Median DSS was 34.25 (31.10, 37.30) for patients who had not 
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received any treatment, 35.60 (30.60, 45.30) for patients with one or two treatment lines 
and 44.00 (33.00, 45.70) for patients with three or more treatment lines (Table 2). 
Although samples from relapsed patients (Fig. 6A) and patients who had received three 
or more treatment lines (Fig. 6B) tended to be more sensitive compared to newly 
diagnosed patients and to patients with less than three lines of treatments, statistically 
significant differences were not observed (p=0.1987 and 0.4113, respectively) (Table 2). 
 
Figure 6. The responses of melflufen in malignant plasma cells among newly diagnosed and relapsed patients, 
and patients with 0, 1-2, and 3 or more lines of treatment. (A) Samples from relapsed patients seemed to be more 
sensitive to melflufen compared to newly diagnosed patients but drug sensitivity scores (DSSs) were not significantly 
higher (p=0.1987). (B) Samples from patients who have received three or more treatment lines tended to be more 
sensitive to melflufen than patients with less than three treatment lines but DSSs were not significantly higher 
(p=0.4113). DSS values are presented as means in Fig. 6A and as medians in Fig. 6B. NS=not significant. 
Second, to observe whether the aggressiveness of the disease and high-risk cytogenetics 
affected the melflufen responses, patients were stratified based on ISS status (1-3) and 
the presence of t(4;14), del(17p) and gain(1q) aberrations (Table 2). Median DSS was 
31.20 (27.90, 38.85) for patients with ISS score 3, 38.75 (26.85, 44.65) for patients with 
score 2, and 38.25 (33.80, 42.70) with score 1. In contrast, mean DSS of melflufen was 
38.84 (SD 6.88) for patients with gain(1q) aberration and 29.77 (SD 6.17) for patients 
without the aberration. Median DSS was 26.85 (23.30, 30.40) for patients with both 
t(4;14) and del(17p) mutations, 42.70 (33.80, 45.30) for patients with only del(17p) 
mutation, 37.30 (33.65, 42.65) for patients with only t(4;14) mutation, and 39.60 (31.80, 
44.00) for patients without either of these mutations (Table 2). 
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Patients with the highest ISS score seemed to be less sensitive to melflufen compared to 
patients with ISS score 1 or 2 (Fig. 7A), while patients with t(4;14), del(17p) and gain(1q) 
seemed to be more sensitive to melflufen than patients without these alterations (Fig. 7B 
and 7C). However, if patients had both t(4;14) and del(17p) alterations, they seemed to 
be even less sensitive to melflufen than wildtype patients (Fig. 7C). However, no 
statistically significant differences were observed between ISS scores (p=0.8606), 
gain(1q) aberration and wildtype (p=0.3638), and between other high-risk cytogenetic 
aberration subgroups (p=0.2319) (Fig. 7, Table 2). 
 
Figure 7. The responses of melflufen in malignant plasma cells among patients with different ISS scores, and 
patients with gain(1q), del(17p) and/or t(4;14) or none of these alterations. (A) Samples from patients with the 
highest ISS score seemed to be less sensitive to melflufen compared to patients with ISS score 1 or 2, but drug sensitivity 
scores (DSSs) were not significantly lower in high ISS score patients (p=0.8606). (B) Samples from patients with 
gain(1q) and (C) other high-risk cytogenetic factors, t(4;14) and del(17p), seemed to be more sensitive to melflufen 
than patients without these alterations. However, patients with both t(4;14) and del(17p) seemed to be less sensitive to 
melflufen than wildtype patients. Yet, significant differences were not observed between gain(1q) and wildtype 
(p=0.3638) and between other high-risk cytogenetic subgroups (p=0.2319). DSS values are presented as medians in 
Fig. 7A and C, and as means in Fig. 7B. NS=not significant, WT=wild type. 
Furthermore, patients were stratified based on age at diagnosis (<65 years and ≥65 years 
old), gender, IgL (kappa and lambda), IgH (IgA and IgG), presence of immunoglobulins 
(IgG, IgA or light chain only) and presence of del(13q) aberration (Table 2). Mean DSS 
was 38.19 (SD 6.07) for patients younger than 65 years and 36.32 (SD 8.73) for patients 
65 years old or older, and 37.23 (SD 8.03) for females and 37.08 (SD 7.62) for males. 
Mean DSS was 34.64 (SD 7.62) for patients with kappa and 41.53 (SD 3.21) for patients 
with lambda IgL, 35.90 (SD 10.87) for patients with IgA and 37.62 (SD 4.84) for patients 
with IgG IgH, and 33.90 (SD 8.75) for patients with only light chain. Furthermore, mean 
DSS was 36.12 (SD 7.78) for patients with del(13q) and 40.20 (SD 6.54) for patients 
without the aberration. Although all patients seemed to be sensitive to melflufen, 
significant differences between subgroups of age, gender, IgL, IgH, presence of 
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immunoglobulins and presence of del(13q) aberration were not detected (p=0.6387, 
0.9700, 0.1644, 0.7380, 0.8016 and 0.3638, respectively) (Appendix 5). 
2.4 Drug responses in lymphocytes 
To observe the cytotoxic effects of melflufen and melphalan in healthy cell populations, 
lymphocytes were used as internal controls. Mean DSS of melphalan was 15.51 (SD 3.51) 
and of melflufen 40.27 (SD 7.22) in lymphocytes (Appendix 3). DSSs of melphalan were 
similar in malignant PCs and lymphocytes (p=0.9460) (Fig. 8A), whereas DSSs of 
melflufen were significantly higher in lymphocytes compared to malignant PCs 
(p=0.0002) (Fig. 8B). 
 
Figure 8. The responses of melphalan and melflufen in lymphocytes. (A) The drug sensitivity scores (DSSs) of 
melphalan were similar in lymphocytes and malignant plasma cells (PCs) (p=0.9460). (B) DSSs of melflufen were 
significantly higher in lymphocytes compared to malignant PCs (p=0.0002). DSS values are presented as means in Fig. 
8A and as medians in Fig. 8B. NS=not significant. 
3 Discussion 
3.1 Melflufen sensitivity 
Despite the evolving treatment landscape and advances of ongoing research, MM remains 
incurable. Although some patients achieve long and durable remission, almost all patients 
will relapse and thus there is an unmet medical need especially regarding treatment of 
RRMM and HRMM patients. In this study, we tested the sensitivity of malignant PCs 
derived from MM patients to melflufen, a novel alkylating anticancer agent, and 
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compared the results to melphalan. Further patient stratification allowed us to detect 
whether there is a specific melflufen-sensitive subgroup(s) of MM patients. When 
comparing DSSs of melflufen and melphalan in malignant PCs, our results showed that 
malignant PCs were more sensitive to melflufen than melphalan (p<0.0001) (Fig. 5A, B 
and C). In addition, there was almost no correlation between melflufen and melphalan 
responses (0.22) and the relationship was lacking significance (p=0.41) (Fig. 5D), 
indicating that the responses of melflufen are not associated with the responses of 
melphalan. These results indicated that melflufen might be more effective than melphalan 
already at reduced doses and if patient is not eligible for melphalan, melflufen treatment 
might be beneficial. 
To observe how RRMM and HRMM patient samples responded to melflufen, drug 
response profiles were compared based on subgroups of disease status and treatment line 
as well as ISS score and high-risk (gain(1q), del(17p) and t(4;14)) cytogenetic markers. 
By comparing DSSs of melflufen in these different subgroups, we evaluated that all 
samples from MM patients including RRMM and HRMM patients seemed to be sensitive 
to melflufen although to varying degrees. Samples from relapsed patients and patients 
with three or more treatment lines tended to be more sensitive to melflufen than samples 
from newly diagnosed patients and patients with 0-2 treatment lines (Fig. 6), although no 
significant differences were observed. However, our results show that RRMM patient 
samples responded well to melflufen treatment. 
Furthermore, samples from patients with the highest ISS score seemed to be less sensitive 
to melflufen compared to patients with lower scores (Fig. 7A), while samples from 
HRMM patients seemed to be more sensitive to melflufen than patients without high-risk 
alterations (Fig. 7B and 7C). However, patients with both t(4;14) and del(17p) alterations 
seemed to be less sensitive to melflufen compared to patient samples without these 
alterations (Fig. 7C), although the significance was lacking. Since samples from patients 
with the highest ISS score and both t(4;14) and del(17p) aberrations did not respond as 
effectively as patient samples with lower ISS score and each mutation alone, it should be 
investigated if patients with individual aberrations benefit from melflufen treatment more 
than patients with several aberrations. Nevertheless, samples from HRMM patient also 
responded to melflufen treatment. 
Although intravenous administration of melflufen affects several cell populations present 
in the body, the response characterisation was limited only in hematopoietic cell types. 
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To observe the cytotoxicity of melflufen, the responses in lymphocytes were detected. 
When comparing DSSs of melflufen in malignant PCs and lymphocytes, lymphocytes 
were even more sensitive to melflufen than malignant PCs (p=0.0002) (Fig. 8B). This 
suggest that melflufen might have some adverse cytotoxic effects. In fact, it has already 
been observed in phase 1-2 clinical studies that the most common severe adverse events 
of melflufen are neutropenia and thrombocytopenia both in solid tumors (Berglund et al., 
2015) and in RRMM (Richardson et al., 2020). Importantly, adverse events observed in 
trials were reversible and clinically manageable in all patients. Nevertheless, cytotoxicity 
should be studied in more detail in the future. Also, drug responses should be studied in 
other cell populations and healthy BM cells for providing a deeper understanding of 
malignant and non-malignant responses and adverse effects. With this approach, dose 
levels with maximal efficacy against malignant PCs and minimal effects towards healthy 
cell populations can be identified. Also, the cycle length of melflufen administration can 
be increased to provide additional time for hematological recovery allowing patients to 
stay on treatment longer (Richardson et al., 2020). 
It is also noteworthy that these specific patients do not respond well to current treatments, 
so it should be studied whether adverse effects of melflufen are milder compared to the 
symptoms and onset of RRMM. There is an ongoing debate on whether MM should be 
treated aggressively with multi-drug combinations aiming at complete response or 
whether MM should be treated in a way that the disease is in control which emphasizes 
the overall survival (OS) and QoL of patients (Rajkumar, 2008). Especially, the predicted 
prognosis for RRMM and HRMM patients is currently extremely poor compared to low 
and standard-risk patients. When using risk stratification model of IMWG (see section 
1.1.3), median OS among low-risk patients is often more than ten years, among standard-
risk patients approximately seven years, and among high-risk patients approximately two 
years (Hanbali et al., 2017; Iriuchishima et al., 2015). Moreover, median OS among 
RRMM patients who are refractory to lenalidomide and bortezomib is only nine months 
(Kumar et al. 2012). 
3.2 Challenges and Future Perspective 
Interpretation of this study was limited by the small sample size. One of the main 
challenges of the assay used in the study was poor viability and low number of malignant 
PCs of the cryopreserved patient samples. Our study was dependent on patient-derived 
samples since they provide a more predictive model to clinical efficacy compared to 
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cancer cell lines. Although in vitro and in vivo studies based on cell line models may 
provide an important understanding of the pathogenesis of MM and drug responses, these 
models cannot mimic the molecular complexity of MM genome. For example, clinical 
drug sensitivity in 57–83%, and drug resistance in 90% accuracy have been predicted 
from in vitro results (Volm and Efferth, 2015), while ex vivo drug sensitivity has been 
proven to have clear relationship with clinical outcome (Majumder et al., 2017; Snijder 
et al., 2017). However, frozen cells are challenging to use since freezing-thawing cycle 
of PCs is quite radical resulting in weak survival of the cells and loss of CD138 expression 
(Dorwal, Thakur and Rawat, 2014; Kawano, et al., 2012). Therefore, some fresh patient-
derived MNCs may be tested for increased viability and the number of malignant PCs. 
Since multiple signaling pathways are activated and clonal heterogenicity is presence in 
MM, the use of combination therapy which can target various molecules simultaneously, 
might be justified (Nijhof et al., 2018). Consequently, when using combination, 
therapeutic efficacy can be achieved at reduced doses of melflufen and thus toxicity and 
adverse effects can be minimized. In fact, previous studies show that melflufen has had 
synergistic effects with bortezomib (Wickström et al., 2008) and induced antagonistic 
effects with docetaxel (Wikström et al., 2007) in vitro. Moreover, the ongoing clinical 
trial which combines melflufen with dexamethasone supports the use of combination 
therapy (“NIH Clinical Trial OCEAN”). Hence, different drug combinations with 
melflufen should be studied ex vivo as well. 
Lastly, there are only few drugs for clinically validated cancer mutations available 
showing how poor the understanding of relationship between complex genome and 
cellular phenotype still is (Friedman et al., 2015). Also, regardless many benefits of 
DSRT, it still lacks standardization needed for more robust and accurate results. Recently, 
a new approach called individualized system medicine (ISM) has been developed for 
acute myeloid leukemia (AML) (Pemovska et al., 2013). It is based on optimizing the 
safest and most effective treatment for each patient as well as trying to understand the 
mechanism of drug resistance by utilizing ex vivo DSRT, clinical implementation of 
predicted effective treatments, and studies of samples from treated patients. Therefore, 
ISM approach implementation for other hematological malignancies including MM may 
improve the understanding of biology of disease and drug resistance (Majumder, 2018; 
Majumder et al., 2017). Additionally, DSRT standardization may lead to better utilization 
of the platform also in clinical use. Furthermore, DSRT platform should be developed 
further so for example BM microenvironment effects on drug responses can be 
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considered. Although the used cell culture medium was from the HS-5 human BM 
stromal cell line mimicking the environment of BM, cell adhesion mediated drug 
responses or hypoxia for example could not be taken into account (Majumder et al., 
2017). 
3.3 Conclusions and summary 
The reason why some patients relapse and what causes drug resistance remains still 
unknown. Possible explanations are for instance the impact of cytogenetic and epigenetic 
alterations, the role of deregulated signaling pathways and the BM microenvironment as 
well as MM cancer stem cells (Abdi et al., 2013). During disease progression, the 
genomic complexity of MM is increasing due to cytogenetic alterations both by the 
number and structure of chromosomes, which are key challenges of MM therapies. Since 
the pipeline for treating MM is one of the most diverse in oncology and more and more 
drugs are getting marketing authorization for MM, determining the best treatment option 
for individual patients becomes more difficult. In addition, newer, usually more expensive 
drugs and many lines of treatment lead to high costs of MM therapies, and the costs are 
expected to rise even more due to aging of the population and extended patient survival 
(Roy et al., 2015). Hence, DSRT platform and ex vivo testing can therefore be clinically 
important approaches and guide which treatments are the most effective for individual 
patients. The significance of the study relies on the linking of data from ex vivo drug 
responses to complex molecular profiles for biomarker discovery, personalized medicine 
development and ultimately improved clinical outcome. Moreover, the results from the 
study are directly translatable to patients and can guide the timing and treatment options. 
In this study, we were able to observe more sensitive melflufen responses in malignant 
PCs from MM patients compared to melphalan ex vivo. Although statistically significant 
melflufen-sensitive subgroups were not observed using standard clinical criteria and 
features, this study showed that all samples from MM patients including RRMM and 
HRMM patients were sensitive to melflufen suggesting these patients may benefit from 
melflufen treatment and thus our results are clinically relevant and valuable. In the future, 
melflufen sensitivity studies may be repeated with drug combinations, cell co-cultures 
and healthy BM samples as well as the mechanism of action of melflufen, especially the 
association of esterases and peptidases to melflufen sensitivity, may be studied. Further 
integration of our drug response results with additional molecular information and clinical 
profiles may lead to discovery of MM specific mutations or gene expression patterns and 
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identification of novel predictive and prognostic biomarkers. Taken together, the 
prediction of melflufen responses and a precision medicine approach can lead to more 
effective disease management, increase QoL of the patients, save patients from extremely 
expensive and ineffective therapies, and reduce the economic burden of MM. 
4 Materials and methods 
4.1 Patient material and sample processing 
BM aspirates were obtained from MM patients (n=51) after signing a written Informed 
Consent Form (ICF) in accordance with the Declaration of Helsinki and the study was 
approved by The Coordinating Ethics Board of Helsinki University Hospital 
Comprehensive Cancer Center (study permits 303/13/03/01/2011 approved on 5.11.2012 
and 239/13/03/00/2010 approved on 12.10.2010). Clinical data have been collected, 
handled and stored appropriately and each patient has been pseudonymized in a way that 
patients cannot be identified. 
Samples were obtained from the Finnish Hematology Clinical Biobank and Registry 
(FHRB, www.fhrb.fi) and selected especially from RRMM and HRMM patients. Briefly, 
samples were processed by isolating MNCs from BM aspirates using Ficoll-Paque 
density gradient centrifugation (Ficoll Paque Premium; GE Healthcare, Chalfont St Giles, 
Buckinghamshire, UK), viably cryopreserved and stored in liquid nitrogen. 
4.2 Reagents, antibodies and controls 
Conditioned medium (CM; 25% conditioned medium from the HS-5 human BM stromal 
cell line in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (FBS), 2 mM 
L-glutamine and 1% penicillin/streptomycin (10 000 units/ml and 10 000 µg/ml, 
respectively)) was used for culturing the cells. Cells were counted with Trypan Blue stain 
0.4% (#T10282; Invitrogen, Waltham, MA, USA), cell counting chamber slides 
(#100078809; Invitrogen) and Countess automated cell counter (Invitrogen). Melflufen 
(Recipharm AB, Stockholm, Sweden) and melphalan (Sigma-Aldrich, St. Louise, MO, 
USA) were dissolved in DMSO (#D4540, Sigma-Aldrich), stored in -80°C as 10 mM 
stock, and thawed in 37°C water bath just prior to use. Antibody dilution mix (AbM, 
Table 3) diluted in staining buffer (SB; 5% FBS in 1 x Dulbecco's phosphate-buffered 
saline (DPBS)) and PE Annexin V Apoptosis Detection kit with 7-AAD (#559763; BD 
Bioscience, Eysins, Switzerland) diluted in mQ were used for MNCs staining. To 
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compensate spectral overlap of fluorescence from several fluorophores, the compensation 
was performed with UltraComp eBeads Compensation Beads (#01-2222; Invitrogen) 
according to their protocol (50 ul/test well). 
Table 3. Information of antibodies and fluorophores of the antibody dilution mix used for staining of 
mononuclear cells on day three. Antibodies were diluted to staining buffer. 
Marker Fluorophore Concentration 
(ng/ul) 
Clone Source Manufacturer Catalogue# Lot 
CD19 BV421 0.2 HIB19 Mouse BD Biosciences 562440 8270584 
CD138 BV605 1.33 MI15 Mouse BD Biosciences 563294 9073759 
CD38 BV786 2.0 HIT2 Mouse BD Biosciences 563964 8304886 
CD45 FITC 0.5 HI30 Mouse BD Biosciences 561865 8134922 
CD56 PE-Cy7 1.0 B159 Mouse BD Biosciences 557747 8340788 
CD319 APC 1.33 162.1 Mouse Biolegend 331810 B260180 
 
4.3 High-throughput drug sensitivity and resistance testing 
CM and the frozen cell vials were warmed and thawed in +37°C water bath. The cells 
were transferred carefully into a falcon tube with CM, and CM was added 1:10 slowly on 
the cells. Cells were centrifuged at 400 x g for 6 min and the supernatant was removed. 
The cell pellet was re-suspended in CM and 50 ul/ml of RQ1 RNase-free DNaseI 
(#M6101; Promega) was added. The cells were incubated at humidified environment at 
+37°C and 5% CO2 for 1h. The cells were then diluted to 2 M cells/ml in CM, transferred 
to a non-treated 6-well plate and incubated overnight at +37°C and 5% CO2. 
On the next day, the cells were mixed gently with a pipette, filtered through a 70 µm cell 
strainer (#22363548; Fisher Scientific, Pittsburg, Pennsylvania, USA) and counted. The 
cells were centrifuged at 400 x g for 6 min and the supernatant was removed. The cell 
pellet was re-suspended in CM in 2 M cells/ml. First, 50 µl of CM was added to control 
wells (0.2% DMSO) of a V-bottom 96-well plate and the plate was shaken with the plate 
shaker for a couple of minutes (750 rpm). Then 100 000 cells/well were dispensed to 
control and drug wells (Fig. 9). Melflufen and melphalan were added directly on top of 
the cells in seven concentrations made fresh in CM ranging from 0.1–100 000 nM as 
duplicates (Fig. 9). The final volume of each well was 100 µl. The plate was shaken with 
the plate shaker for a couple of minutes (450 rpm) and incubated at +37°C and 5% CO2 
for 72 h. For the day 0 control, which was performed to check the viability and number 
of malignant PCs, two wells of an empty 96-well plate were plated with 100 000 cells/well 
and centrifuged at 500 x g for 6 min. The supernatant was removed by turning the plate 
upside down. 25 µl of AbM was added to the staining well and 25 µl of SB to the 
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unstaining well. The plate was incubated at RT for 30 min in the dark. 100 µl of SB was 
added to wells for washing and the plate was centrifuged at 500 x g for 6 min. 
Supernatants were removed and 25 µl of Annexin V Apoptosis Detection solution was 
added to each well. The plate was shaken with the plateshaker for a couple of minutes 
(450 rpm). The plate was read with a high-throughput flow cytometer (iQue Screener 
Plus, Sartorius, Albuquerque, NM, USA). For the day 3 DSRT analysis, the same staining 
protocol was repeated for treated cells after 72 h incubation. 
 
Figure 9. Layout of 96-well drug plate. Melflufen and melphalan concentrations were ranging from 0.1–100 000 nM 
as duplicates. DMSO was used as negative control. In addition to melflufen and melphalan, other drugs were also tested 
in the same plate but the results were not included in this thesis. 
4.4 Data analysis 
4.4.1 Sample selection criteria 
Out of 51 tested samples, 16 were chosen for further data analysis based on reasonable 
cell viability (viability >25%) and constant number of CD138+/CD38+ (malignant PCs) 
cells in control DMSO wells (>50 cells) for data normalization (Appendix 1). Moreover, 
samples should have had enough malignant PCs in the drug wells for creating robust dose-
response. Also, samples were not chosen for data analysis if there were problems with 
antibody staining or flow cytometer run (Appendix 1). 
4.4.2 Gating and dose-response curves 
DSRT readouts were analysed with ForeCyt software (Sartorius) and the counts of 
different cell populations including malignant PCs and lymphocytes were observed by 
utilising specific antibodies (Table 3). Gating strategy is presented in Figure 10. All cells 
were detected with FSC and SSC, single cells were detected from all cells with FSC 
height (FSC-H) and FSC area (FSC-A). Live, apoptotic and dead cells were separated 
using annexin V and 7-AAD. Malignant PCs were separated from other live cell 
populations with anti-CD138 and anti-CD38 antibodies (Flores-Montero et al., 2016; 
Melflufen Melphalan Melflufen Melphalan
1 2 3 4 5 6 7 8 9 10 11 12
A  0,1  0,1    0,1  0,1   
B  1  1    1 1   
C  10 10    10 10   
D DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO DMSO
E  100 100    100 100   
F  1000  1000    1000  1000   
G  10000  10000    10000  10000   
H  100000  100000    100000  100000   
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Jelinek et al., 2017) whereas lymphocytes were separated with anti-CD45 antibody and 
low SSC (Akanni and Palini, 2006). 
 
Figure 10. Gating strategy. All cells were detected with FSC and SSC, single cells were detected from all cells with 
FSC height (FSC-H) and FSC area (FSC-A). Live, apoptotic and dead cells were separated with annexin V and 7-AAD. 
Malignant PCs were separated from other live cell populations utilizing anti-CD138 and anti-CD38 antibodies whereas 
lymphocytes were separated utilizing anti-CD45 antibody and low SSC. BL4, BL2, VL6, VL4 and BL1 are channels 
of flow cytometer. 
GraphPad Software (GraphPad Prism 8.4.2, San Diego, CA, USA) was used for nonlinear 
regression analysis and for generating logistic dose-response curves to melflufen and 
melphalan. The data was normalized to means of the highest and lowest concentrations 
of drug duplications of each sample. 
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4.4.3 Drug sensitivity score 
Drug sensitivity score (DSS), an approach used for creating a single metric from 
multiparametric dose-response relationships which takes into account IC50, slope 
maximal and minimal response as well as minimal activity (Yadav, B. et al., 2015), to 
each patient was obtained from FIMM’s main data repository (TheDB). It has been shown 
that two samples can have equal single model parameters, for example IC50 values, while 
having different activity patterns (Yadav, B. et al., 2015). Therefore, in some cases IC50 
is not informative enough to detect the differences in response patterns of patient samples, 
and thus DSS is used in this study to identify selective drug response patterns. The higher 
DSS associates with smaller IC50 value and reflects higher sensitivity of the sample. 
4.4.4 Statistical analysis 
Statistical analysis were done with GraphPad Prism. Normal distribution assumption for 
DSSs was checked visually using normal quantile plot and with Shapiro-Wilk test. Mean 
and standard deviation (SD) are reported for normally distributed variables, and median 
with 25% and 75% quartiles (Q1, Q3) to nonparametric variables. Differences were 
considered statistically significant when associated with a p-value of <0.05, and highly 
significant with <0.001. 
The difference of melflufen and melphalan responses in malignant PCs was obtained by 
comparing DSSs with paired two-sample t-test. PC specific drug sensitivity was obtained 
by comparing DSSs of melflufen with Wilcoxon signed rank test and DSSs of melphalan 
with paired two-sample t-test in malignant PCs and lymphocytes. Correlation of 
melflufen and melphalan responses (DSS) of malignant PCs was analysed with Pearson 
correlation. 
Since all samples seemed to be sensitive to melflufen, to identify melflufen-sensitive 
subgroup, the responses of melflufen in malignant PCs were stratified into more (IC50 
<50nM) and less (IC50 >50nM) sensitive subgroups, rather than sensitive and resistant 
groups, based on IC50 values. Further, to assess whether clinical characteristics (Table 2) 
influence the responses of melflufen in malignant PCs, MM patients were stratified into 
different subgroups based on disease status (diagnosis, relapse), age at diagnosis (<65 
years and ≥65 years old), gender (females and males), IgL (kappa and lambda), IgH (IgA 
and IgG), presence of immunoglobulins (IgG, IgA and light chain only), ISS score (1-3), 
lines of treatment (0, 1-2, ≥3) and the presence of del(13q), gain(1q), del(17p) and t(4;14) 
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aberrations. DSSs of melflufen in sensitivity, disease status, age, gender, IgL, IgH as well 
as del(13p) and gain(1q) aberration subgroups were compared with unpaired t-test. DSSs 
of melflufen in ISS, treatment lines and genetic aberrations (del(17p) and/or t(4;14), or 
neither of them) subgroups were compared with Kruskal-Wallis test. DSSs of melflufen 
in immunoglobulin subgroups were compared with one-way ANOVA test.
27 
 
5 Acknowledgements 
This project has been conducted at FIMM, Institute for Molecular Medicine Finland, 
which works as a part of Helsinki Institute of Life Science (HiLIFE) and the University 
of Helsinki. The study was funded by a research grant from Oncopeptides AB to Caroline 
Heckman, and I would like to thank Oncopeptides AB for this great opportunity to work 
with their new anticancer drug. Donations of samples from patients and Finnish 
Hematology Clinical Biobank and Registry (FHRB) are also gratefully acknowledged for 
the valuable patient material. 
I would like to express the greatest appreciation and gratitude to my supervisors Dr. 
Caroline Heckman and Dr. Juho Miettinen. Your professional supervision and guidance 
throughout the whole project, as well as your enthusiasm and interest towards 
personalized medicine have been important and motivated me. Your deep knowledge and 
years of experience have got me to enhance my understanding of the topic and skills both 
theoretically and practically. During my time at FIMM, especially my scientific 
skepticism and critical way of thinking have improved a lot. 
I would also like to express my sincere gratitude to Alun and Minna, our sample 
processing experts, and to every Translational Research and Personalized Medicine group 
member (Joseph, Dimitrios, Vilma, Ida, Simo, Jarno, Riikka, Heikki, Amanda, Philipp, 
Komal, Romika, Sofia, Sadiksha, Ashwini, Minxia, Alina, Annukka, Markus and 
Mahesh). I’m more than grateful for all the help, guidance, advice, shared expertise, 
meetings and coffee breaks, and I have been honored to be a part of this talented group. 
Also, I would like to acknowledge all FIMM personnel who have created an inspiring 
working environment. Finally, I would like to warmly thank my classmates for the peer 
support and shared years of Biomedical Sciences program. 
Thank you.
28 
 
6 Abbreviations list 
β2-M   β2-Macroglobulin 
BM   Bone Marrow 
CD   Cluster of Differentiation 
CM   Conditioned Medium 
DSRT   Drug Sensitivity and Resistance Testing 
DSS   Drug Sensitivity Score 
FSC   Forward Scatter 
HRMM  High-Risk Multiple Myeloma 
IgH   Immunoglobulin Heavy chain 
IgL   Immunoglobulin Light chain 
IMWG   International Myeloma Working Group 
ISS   International Staging System 
MGUS   Monoclonal Gammopathy of Undetermined Significance 
MM   Multiple Myeloma 
MNC   Mononuclear Cell 
NA   Not Available 
OS   Overall Survival 
PC   Plasma Cell 
QoL   Quality of Life 
RRMM  Relapsed and Refractory Multiple Myeloma 
SB   Staining Buffer 
SMM   Smoldering Myeloma 
SSC   Side Scatter 
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8 Appendices 
Appendix 1. A list of tested samples and selection criteria for data analysis. Out of 51 tested samples, 16 were 
chosen for further data analysis based on reasonable cell viability (>25%) and number of malignant plasma cells (PCs) 
in DMSO wells (>50 cells). Moreover, samples should have had enough malignant PCs in the drug wells for creating 
the robust dose-response curves. Also, samples were not chosen for data analysis if there were problems with antibody 
staining or flow cytometer run. NA= not available. DG=diagnosis, RRMM=relapsed and refractory multiple myeloma. 
Sample ID 
Flow-based 
viability on day 3 
(%) 
Average number 
of PCs in DMSO 
well on day 3 
Comments 
MM01 31.8 138.4 
Chosen for data analysis 
MM02 35.9 1708 
MM03 37.8 360.8 
MM04_DG 49.8 6912.6 
MM04 RRMM 50.4 53.6 
MM06 68.4 850.8 
MM07 63.4 2092.9 
MM08 47.8 257.4 
MM09 54.1 559.3 
MM10 29.9 558.3 
MM11 57.0 1777.4 
MM12 40.1 2430.7 
MM13 50.6 153.2 
MM14 61.5 70.3 
MM15 79.0 220.4 
MM16 53.7 1636 
mean 50.7 1236.26  
MM17 38.5 38.5 
Low number of PCs 
MM18 50.7 9 
MM19 26.6 27.3 
MM20 25.4 2.6 
MM21 45.2 3.1 
MM22 38.6 32.1 
MM23 15.5 127.6 
Poor viability 
MM24 8.4 625.4 
MM25 12.1 32.7 
Low number of PCs and poor 
viability 
MM26 11.4 15.1 
MM27 13.9 6.1 
MM28 0.0 11 
MM29 13.4 7.9 
MM30 21.0 2 
MM31 13.9 19.9 
MM32 NA NA 
Low number of PCs and poor 
viability already on day 0, and 
thus DSRT was not run on day 
3 for treated cells 
MM33 NA NA 
MM34 NA NA 
MM35 NA NA 
MM36 NA NA 
MM37 NA NA 
MM38 73.3 110.3 Variable number of cells in 
drug wells causing problems 
for determining dose response 
MM39 37.5 324.3 
MM40 68.2 83 
MM41 35.5 345.9 
MM42 18.0 NA 
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MM43 53.0 NA 
Variable number of cells in 
DMSO wells leading to 
problems with normalization 
MM44 27.4 NA Problems with antibody 
staining MM45 33.9 NA 
MM46 35.9 176.4 
Clog during flow run 
MM47 55.0 1430.5 
MM48 NA NA 
MM49 NA NA 
MM50 41.2 218.3 
MM51 53.2 134.3 
 
Appendix 2. Detailed clinical characteristics of each patient. R=RRMM=relapsed and refractory multiple myeloma, 
D=DG=diagnosis, F=female M=male, ISS=international staging system, IgH=immunoglobulin heavy chain, 
IgL=immunoglobulin light chain, NA=not available. 
Sample 
ID 
Age at 
diagnosis 
Disease 
status 
Gender Treatment 
line 
ISS IgH IgL del 
(13q) 
gain 
(1q) 
High-risk 
cytogenetics 
MM01 61 R M 1 1 NA kappa NA x del17p 
MM02 51 R M 1 3 IgG kappa x x t(4;14) 
MM03 74 R M 4 2 NA NA x x none 
MM04 
DG 
77 D M 0 2 IgA kappa x NA both 
MM04 
RRMM 
77 R M 5 2 IgA kappa x NA both 
MM06 58 R F 1 2 IgG kappa x x del17p 
MM07 77 R M 5 1 NA lambda x x del17p 
MM08 55 R F 2 NA IgG kappa x NA none 
MM09 73 R M 3 NA IgA lambda x x none 
MM10 37 R M 9 NA NA NA x x t(4;14) 
MM11 69 D F 1 3 NA kappa x x none 
MM12 70 D F 0 3 NA NA x x none 
MM13 77 D F 2 3 IgA kappa x x none 
MM14 71 D F 1 2 IgG kappa x x none 
MM15 58 D M 0 NA IgG kappa x x t(4;14) 
MM16 55 D M 0 2 IgG lambda x x t(4;14) 
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Appendix 3. Drug sensitivity scores (DSSs) of melflufen and melphalan in malignant plasma cells (PCs) and 
lymphocytes. *=statistically significant difference.  
Drug Cell population DSS (SD) p 
Melflufen 
Melphalan 
Malignant PCs 37.14 (7.51) 
15.47 (4.76) 
<0.0001* 
Melflufen Malignant PCs 
Lymphocytes 
37.14 (7.51) 
40.27 (7.22) 
0.0002* 
Melphalan Malignant PCs 
Lymphocytes 
15.47 (4.76) 
15.51 (3.51) 
0.9460 
 
 
Appendix 4. The stratified responses of melflufen by IC50 values in malignant plasma cells. (A) The responses of 
melflufen in malignant plasma cells from MM patient samples were stratified based on IC50 values into more (<50nM, 
blue) and less (>50nM, orange) sensitive groups. (B) When drug sensitivity scores (DSSs) of melflufen between these 
sensitivity groups were compared, significant difference was not detected (p=0.1599). NS=not significant. 
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Appendix 5. The responses of melflufen in malignant plasma cells among patients stratified by age at diagnosis, 
gender, immunoglobulin light and heavy chains and presence of del(13q) aberration. MM patients were stratified 
based on (A) age at diagnosis (<65 years and ≥65 years old), (B) gender (females and males), (C) immunoglobulin light 
(kappa and lambda) and (D) heavy chains (IgA and IgG), (E) presence of immunoglobulins (IgG, IgA or light chain 
only), and (F) presence of del(13q) aberration. Although all patients seemed to be sensitive to melflufen, significant 
differences between subgroups were not detected (p=0.6387, 0.9700, 0.1644, 0.7380, 0.8016 and 0.3638, respectively). 
DSS=drug sensitivity score, NS=not significant, WT=wild type. 
